BioSpace News Archive

NervGen remains on track to initiate its Phase 1 program for NVG-291 in healthy volunteers in Q1 2021 with plans to report top-line results from the single and multiple dose portion of the study in the second half of 2021.

Delta Dental of Arkansas provided $27.4 million in direct COVID-19 relief funding in 2020 while also enacting rate holds, offering grace periods for premium payments, easing eligibility requirements for coverage, retaining its full workforce and facilitating telecommuting for most of its employees.

Vizient, Inc. today released its Winter 2021 Pharmacy Market Outlook, projecting a 2.67% increase in the price of pharmaceuticals purchased by health systems, academic medical centers, pediatric hospitals, and non-acute practices, for the period July 1 – June 30, 2022.

Infrared Cameras, Inc. (ICI), the leader in advanced biorisk-management technology, and Viral Sign, Inc. (Viral Sign), an innovator in the use of infrared technology and advanced screening software to detect viral infection, are pleased to announce a strategic alliance to supply advanced screening systems intended to help slow the spread of infectious disease, including COVID-19.

Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, reports that it sold 25,947 boxes of Endari® in 2020 compared to 24,797 boxes in 2019, an increase of 5%.

“The full-year results reflect our commitment and focus to maintaining operations throughout the COVID-19 pandemic, while making an active and decisive contribution to controlling it.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has closed on the sale to certain institutional and accredited investors of approximately $20.0 million

Scientists from the J. Craig Venter Institute (JCVI) have discovered that Influenza A virus (IAV) is found in heart tissue after it has been cleared from the lungs in mouse models.

Intercept Pharmaceuticals, Inc. announced that an analyst note commenting on the listing of Intercept’s product on the U.S. Food and Drug Administration Adverse Event Reporting System website reached a conclusion regarding the status of a newly identified safety signal for Ocaliva® that the Company believes is incorrect.

The Government remains committed to a national, universal pharmacare program and will accelerate steps to achieve this system including through a rare-disease strategy to help Canadian families save money on high-cost drugs.